Article
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
PloS one - 1 Jan 2013
Shen Yinchen, Wang Jianfei, Han Xiaohong, Yang Hongying, Wang Shuai, Lin Dongmei, Shi Yuankai
Abstract excerpt
Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epidermal growth factor receptor (EGFR) antibody therapies. However, some patients with KRAS wild-type tumors still do not respond, so other downstream mutations in BRAF, PIK3CA and NRAS should be investigated. Herein we used direct sequencing to analyze mutation status for 676 patients in KRAS (codons 12, 13 and 61), BRAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.